Ipamorelin has genuine, direct pharmacokinetic data from human trials involving intranasal administration. This is a key distinguishing feature compared with many of the other peptides discussed in this series. However, the same studies have shown that intranasal administration is significantly less effective than injection. No equivalent human studies exist for oral capsule or tablet forms, which face the same fundamental problem of digestive breakdown common to peptides in general.
Ipamorelin nasal spray
Unlike CJC-1295, for which there is no dedicated study on intranasal bioavailability, ipamorelin has in fact been directly tested via the intranasal route in human-like controlled pharmacokinetic studies. This makes it an area that is truly evidence-based, rather than mere speculation. A pharmacokinetic study specifically comparing ipamorelin with other related peptide growth hormone stimulators showed that the bioavailability of ipamorelin following intranasal administration was approximately 20%. This means that roughly one-fifth of the administered dose reached the systemic circulation compared with injection [1].
This is a valid and useful data point. However, it is important to understand what it tells us. 20% represents a significantly reduced absorption rate compared with injection. The same studies showed that several structurally related compounds tested in these trials achieved higher intranasal bioavailability, closer to 50%. This suggests that the chemical structure of ipamorelin may make it comparatively less effective at crossing the nasal mucosa than some of its close chemical relatives [1].
This finding demonstrates that intranasal absorption of this general family of peptides is biologically real and measurable. However, it also means that, based on these specific published studies, a nasal spray would be expected to deliver a significantly lower active dose into the bloodstream than an equivalent amount administered by injection.
It is worth noting that this pharmacokinetic study measured absorption into the bloodstream — not necessarily the resulting growth hormone response or any downstream clinical outcome specifically associated with intranasal administration. Therefore, whilst the bioavailability figure itself is well documented, its practical significance for the hormonal response following the use of a nasal spray in an actual product has not been separately confirmed by additional studies.
Ipamorelin oral capsules, tablets and pills
Ipamorelin, as a peptide consisting of a chain of five amino acids, would be expected to face the same fundamental barrier that affects peptide drugs as a category when taken orally. Digestive enzymes in the stomach and intestines, combined with the highly acidic gastric environment, generally break down peptides before they can be absorbed intact. Even fragments that survive encounter poor absorption through the intestinal wall due to their size and chemical properties [2]. This is a well-established, general principle of peptide pharmaceutical science, rather than a marketing-specific claim. None of the published pharmacokinetic studies identified in this review measured the oral bioavailability of ipamorelin specifically to confirm or refute how significantly this barrier applies to it in practice.
As discussed in relation to CJC-1295 elsewhere in this series, achieving significant oral bioavailability for this general class of compounds has historically required deliberate chemical re-engineering. A related but structurally distinct molecule, specifically designed to survive digestion by modifying the basic peptide backbone, achieved true oral bioavailability in animal studies. However, this involved a completely different, specially designed compound — not standard ipamorelin itself [3].
Based on the general principles of peptide pharmacology and the lack of any dedicated oral bioavailability studies for unmodified ipamorelin, oral capsules, tablets, or pills containing standard ipamorelin peptide would not be expected to reliably deliver an effective, intact dose into systemic circulation. There is no clinical evidence to support oral formulations as an established, effective route for this particular compound.
Pens and injection devices for Ipamorelin
As regards the size of the needle for injection, clinical trials of ipamorelin used intravenous infusion rather than self-administered subcutaneous injection [4], [5]. This means that no published study specifies the size or length of the needle used in the context of self-injection, as this is a practical, clinical detail relevant to home administration, rather than a scientific finding reported in the resulting research articles. As a general background applicable to subcutaneous peptide injections more broadly—and not specific to ipamorelin studies—needles commonly used for this general purpose are typically short and fine. They are often in the range of 29 to 31 gauge and approximately 4 to 8 millimetres in length. This reflects the standard practice of reaching the subcutaneous fat layer without penetrating deeper into the muscle. This is a general injection convention derived from broader practices in the administration of peptides and insulin — it is not a validated recommendation specific to ipamorelin studies or pen-type devices.
As regards pen-type devices specifically for ipamorelin, none of the peer-reviewed studies identified in this series evaluated such a device for this compound. As discussed for CJC-1295 elsewhere in this series, a „pen” is simply an alternative delivery mechanism for the same basic peptide solution, rather than a distinct, separately studied formulation.
Limitations of current evidence
The intranasal bioavailability of ipamorelin, at approximately 20%, is well documented by direct pharmacokinetic studies. This makes it one of the best-characterised routes of administration discussed anywhere in this series [1]. It is worth noting, however, that this figure describes absorption into the bloodstream, rather than a confirmed hormonal or clinical outcome specifically from intranasal spray products.
The oral capsule and tablet formulations are not supported by any dedicated bioavailability studies. General principles of peptide pharmacology suggest that they would undergo significant degradation prior to absorption [2]. Information on needle size and injection devices reflects general practice across the administration of peptides, rather than validated studies specific to ipamorelin.
Disclaimer
Ipamorelin has not been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any equivalent regulatory body for any use in humans, in any form of administration, including nasal spray, oral capsules, tablets or injections. It is not manufactured or sold under the quality and safety controls that apply to authorised pharmaceuticals. The information in this article is based on published pharmacokinetic studies and general principles of peptide pharmacology, and does not establish that any specific route of administration is safe or effective for general use. This article is provided solely for general educational and informational purposes, reflects the state of the published scientific literature at the time of writing, and does not constitute medical advice. It does not constitute administration instructions, and nothing in it should be interpreted as a recommendation to use, obtain or administer ipamorelin in any form.
References
[1] Johansen, P. B., Hansen, K. T., Andersen, J. V., & Johansen, N. L. (1998). Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica, 28(11), 1083–1092. https://doi.org/10.1080/004982598238976
[2] Chen, G., Kang, W., Li, W., Chen, S., & Gao, Y. (2022). Oral delivery of protein and peptide drugs: From non-specific formulation approaches to intestinal cell targeting strategies. Theranostics, 12(3), 1419–1439. https://doi.org/10.7150/thno.61747
[3] Hansen, B. S., Raun, K., Nielsen, K. K., Johansen, P. B., Hansen, T. K., Peschke, B., Lau, J., Andersen, P. H., & Ankersen, M. (1999). Pharmacological characterisation of a new oral GH secretagogue, NN703. European Journal of Endocrinology, 141(2), 180–189. https://doi.org/10.1530/eje.0.1410180
Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modelling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
[5] Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomised, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8